Relafen 750 mg, a noncopyrightal anti-inflammatory drug (NSAID), exhibits significant biochemical attributes that contribute to its therapeutic action. A comprehensive analysis of these properties uncovers valuable insights into the mechanism of action and potential clinical implications. The drug's primary target is the inhibition of cyclooxygenas